Richard Saynor, Sandoz CEO (Pascal Mora/Bloomberg via Getty Images)

Co­herus sells San­doz its Lu­cen­tis biosim­i­lar for $170M to fo­cus on on­col­o­gy as­sets 

Co­herus Bio­Sciences is sell­ing its FDA-ap­proved oph­thal­mol­o­gy biosim­i­lar Cimer­li — a copy­cat ver­sion of Roche’s Lu­cen­tis — to San­doz for $170 mil­lion in cash to fo­cus on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.